Descrizione

The global drug discovery market is poised to grow by US$ 44.3 miliardi da 2022 A 2028, registrando un CAGR di 8.7% durante il periodo di previsione, secondo StrategyHelix.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2018-2021 e previsione a 2028 covering key market aspects like sales value for drug discovery. The global drug discovery market is segmented on the basis of type, drug type, disease application, end user, e regione. Per tipo, the global drug discovery market has been segmented into bioanalytical instruments, bioinformatics, cell-based assays and reagents, genomics, high-throughput screening, proteomics, altri. The bioanalytical instruments segment was the largest contributor to the global drug discovery market in 2021. Based upon drug type, the global drug discovery market is categorized into biologics, small-molecule drugs. On the basis of disease application, the global drug discovery market has been segmented into cancer, cardiovascular, immunological, neurological, altri. The cancer segment held the largest revenue share in 2021. By end user, the global drug discovery market has been segmented into academia and research institutes, contract research organizations (CROs), pharmaceutical companies. In termini di geografia, the global drug discovery market has been segmented into Asia Pacific, Europa, Nord America, Rest of the World (RoW).

The global drug discovery market is highly competitive. The competitive landscape of the industry has also been examined along with the profiles of the key players Agilent Technologies Inc., AMETEK Inc., Arrayit Corp., Becton Dickinson and Company, Biomax Informatics AG, Bio-Rad Laboratories Inc., Bruker Corp., Charles River Laboratories Inc., Danaher Corp., General Electric Company (GE), Hitachi High-Technologies Corporation, Illumina Inc., JEOL Ltd., LECO Corporation, Merck KGaA, Perkin Elmer Inc., Qiagen N.V., Roche Holding AG, Shimadzu Corporation, Thermo Fisher Scientific Inc.

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the drug discovery market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Tipo: bioanalytical instruments, bioinformatics, cell-based assays and reagents, genomics, high-throughput screening, proteomics, altri
Drug type: biologics, small-molecule drugs
Disease application: cancer, cardiovascular, immunological, neurological, altri
Utente finale: academia and research institutes, contract research organizations (CROs), pharmaceutical companies
Regione: Asia Pacifico, Europa, Nord America, Rest of the World (RoW)
Anni considerati: la presente relazione copre il periodo 2018 A 2028

Principali vantaggi per gli stakeholder

– Get a comprehensive picture of the global drug discovery market
– Individuare i settori in crescita e le tendenze per gli investimenti

Sommario

Parte 1. introduzione
– Ambito dello studio
– Periodo di studio
– Ambito geografico
– Metodologia di ricerca
Parte 2. Drug discovery market overview
Parte 3. Market breakdown by type
– Bioanalytical instruments
– Bioinformatics
– Cell-based assays and reagents
– Genomics
– High-throughput screening
– Proteomics
– Altri
Parte 4. Market breakdown by drug type
– Biologics
– Small-molecule drugs
Parte 5. Market breakdown by disease application
– Cancer
– Cardiovascular
– Immunological
– Neurological
– Altri
Parte 6. Market breakdown by end user
– Academia and research institutes
– Contract research organizations (CROs)
– Pharmaceutical companies
Parte 7. Market breakdown by region
– Asia Pacifico
– Europa
– Nord America
– Rest of the World (RoW)
Parte 8. Aziende chiave
– Agilent Technologies Inc.
– AMETEK, Inc.
– Arrayit Corp.
– Becton, Dickinson and Company
– Biomax Informatics AG
– Bio-Rad Laboratories, Inc.
– Bruker Corp.
– Charles River Laboratories, Inc.
– Danaher Corp.
– General Electric Company (GE)
– Hitachi High-Technologies Corporation
– Illumina, Inc.
– JEOL Ltd.
– LECO Corporation
– Merck KGaA
– Perkin Elmer Inc.
– Qiagen N.V.
– Roche Holding AG
– Shimadzu Corporation
– Thermo Fisher Scientific Inc.
Informazioni su StrategyHelix
Disclaimer